Controversies on HDL: Should it be a target biomarker in patients with lipid disorders?

Stephen J. Nicholls, Jordan Andrews, Ngan MyDuong

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility. This review will reflect on challenges faced in developing new effective HDL targeted therapies.

LanguageEnglish
Pages649-652
Number of pages4
JournalCurrent Vascular Pharmacology
Volume12
Issue number4
DOIs
Publication statusPublished - 2014

Keywords

  • Atherosclerosis
  • High-density lipoproteins
  • Lipids
  • Risk factors

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Nicholls, Stephen J. ; Andrews, Jordan ; MyDuong, Ngan. / Controversies on HDL : Should it be a target biomarker in patients with lipid disorders?. In: Current Vascular Pharmacology. 2014 ; Vol. 12, No. 4. pp. 649-652.
@article{d8a2e4bb8c1442bf8c324f40f4a7d08a,
title = "Controversies on HDL: Should it be a target biomarker in patients with lipid disorders?",
abstract = "Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility. This review will reflect on challenges faced in developing new effective HDL targeted therapies.",
keywords = "Atherosclerosis, High-density lipoproteins, Lipids, Risk factors",
author = "Nicholls, {Stephen J.} and Jordan Andrews and Ngan MyDuong",
year = "2014",
doi = "10.2174/1570161112999140411131155",
language = "English",
volume = "12",
pages = "649--652",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

Controversies on HDL : Should it be a target biomarker in patients with lipid disorders? / Nicholls, Stephen J.; Andrews, Jordan; MyDuong, Ngan.

In: Current Vascular Pharmacology, Vol. 12, No. 4, 2014, p. 649-652.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Controversies on HDL

T2 - Current Vascular Pharmacology

AU - Nicholls, Stephen J.

AU - Andrews, Jordan

AU - MyDuong, Ngan

PY - 2014

Y1 - 2014

N2 - Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility. This review will reflect on challenges faced in developing new effective HDL targeted therapies.

AB - Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility. This review will reflect on challenges faced in developing new effective HDL targeted therapies.

KW - Atherosclerosis

KW - High-density lipoproteins

KW - Lipids

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84904724315&partnerID=8YFLogxK

U2 - 10.2174/1570161112999140411131155

DO - 10.2174/1570161112999140411131155

M3 - Review article

VL - 12

SP - 649

EP - 652

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 4

ER -